Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $144
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and increased the price target from $141 to $144.
December 18, 2023 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Paul Matteis maintains a Buy rating on Neurocrine Biosciences and raises the price target from $141 to $144.
The increase in price target by Stifel reflects a positive outlook on Neurocrine Biosciences, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100